Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 5/20 | 0.59 |
| ▸ | SRC | P12931 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.56 |
| ▸ | ABL1 | P00519 | 4/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.56 |
| ▸ | HCK | P08631 | 4/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.56 |
| ▸ | MTOR | P42345 | 4/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.56 |
| ▸ | PRKDC | P78527 | 4/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | BTK | Q06187 | 5/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317335 | 1.00 | ITK (0.59) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL1317738 | 1.00 | ITK (0.59) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL1317672 | 0.90 | KDR (0.58) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL1317675 | 0.90 | KDR (0.58) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL1319544 | 0.90 | KDR (0.58) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL12120723 | 0.88 | LCK (0.56) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL12120739 | 0.88 | LCK (0.56) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL1320677 | 0.86 | ITK (0.59) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL1317962 | 0.86 | ITK (0.59) | ITKSRCKDREPHB4PIK3CD | |
| SCHEMBL1317957 | 0.86 | ITK (0.59) | ITKSRCKDREPHB4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8697709-B2 | Fused ring heteroaryl kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2010045542-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | XBP1, DNAJC10, HSPA5 | ITK 4490/4885SRC 4225/4885KDR 4859/4885 |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | ITK 735/4885SRC 180/4885KDR 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.